GlaxoSmithKline (GSK)
Your Dashboard
Displaying GSK Charts
Personalize your Dashboard. You can add and remove charts, drag and drop them into the order you
like, and we'll save your settings for the next time you visit when you're logged in.
Log in here or Click here to register for your free account.
Select or add more charts
- Accounts Payable 11.09B
- Accounts Receivable 9.038B
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization 0.6623
- Beneish M-Score Pro
- Beta Pro
- Book Value 15.04B
- Book Value per Share 5.961
- Capital Expenditures 248.21M
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing -1.935B
- Cash Financing TTM -9.835B
- Cash Investing 204.23M
- Cash Investing TTM -1.312B
- Cash Operations 1.590B
- Cash Operations TTM 10.04B
- Cash and Equivalents 8.625B
- Cash and ST Investments 9.173B
- Current Ratio 1.120
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio 1.537
- Dividend
- Dividend Yield 4.99%
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share 0.85
- Earnings Per Share Growth -10.53%
- Earnings Per Share TTM 3.19
- Earnings Yield 7.19%
- Effective Tax Rate TTM Pro
- Enterprise Value 126.24B
- Expenses 8.579B
- Expenses TTM 35.86B
- Free Cash Flow 1.342B
- Free Cash Flow TTM 8.721B
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin 73.47%
- Gross Profit TTM 32.23B
- Income from Cont. Ops Pro
- Interest Expense 0.00
- Interest Income
- Inventories 6.297B
- KZ Index Pro
- Liabilities 49.06B
- Long Term Debt 18.84B
- Market Cap 112.00B
- Net Income 2.139B
- Net Income TTM 8.104B
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio 13.91
- PE Value Pro
- PEG Ratio 0.0753
- PS Value Pro
- Payout Ratio TTM Pro
- Price 44.38
- Price / Book Value 7.445
- Price / Sales Ratio 2.548
- Price / Tangible Book Value Pro
- Profit Margin 19.95%
- R&D Expense 1.525B
- Receivables Turnover 4.725
- Retained Earnings 6.215B
- Retained Earnings Growth -37.59%
- Return on Assets 12.15%
- Return on Equity 54.98%
- Return on Invested Capital Pro
- Revenue Growth 1.64%
- Revenue Per Share TTM 17.42
- Revenues 10.72B
- Revenues TTM 43.96B
- SG&A Expense 3.346B
- Shareholders Equity 15.04B
- Shares Outstanding 2.524B
- Stock Buybacks 218.36M
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets 64.10B
- Total Return Price 44.38
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
What do these terms mean? Read all about them in the Glossary.
You may also be interested in these GSK related companies
GSK News
@mydanilo It had nothing to do with those news. That was already priced in. Seems like Patent news regarding $TEVA and $GSK was the trigger.
about 6 hours ago by mitrado
about 6 hours ago by mitrado
$AMRN up following news that $Teva and $PRX lost a bid to sell the generic form of $GSK Lovaza. http://stks.co/41F0
about 8 hours ago by abubnic
about 8 hours ago by abubnic
Teva (TEVA), Par Pharma (NPRX) said to lose bid to sell the generic form of Glaxo's (GSK) Lovaza
May 29, 3:20PM Street Insider
May 29, 3:20PM Street Insider
$GSK reacts to $HGSI poison pill. Stubborn, or what? It seems they do not want to get pushed or pulled.
about 7 days ago by OysterX
about 7 days ago by OysterX
GlaxoSmithKline Amends HGS Tender Offer to Address Poison Pill, Requires HGS to Redeem Pill
May 23, 8:37AM Benzinga
May 23, 8:37AM Benzinga
Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Bumping Guidance on Testim Partnership with GSK
May 22, 8:42AM Street Insider
May 22, 8:42AM Street Insider
Auxilium Pharma (AUXL), Glaxo (GSK) Enter Testim 1% Co-Promotion Agreement
May 21, 7:03AM Street Insider
May 21, 7:03AM Street Insider
Glaxo (GSK) Comments on Human Genome (HGSI) Bid Rejection; Will Continue with $13/Share Tender
May 17, 1:17PM Street Insider
May 17, 1:17PM Street Insider
Still think that $GSK will not succeed with $HGSI takeover at 13/share. They will increase the offer price, but probably not above 15.
about 13 days ago by OysterX
about 13 days ago by OysterX
News related to $GSK, currently 0.0% since open: 'Prestige Brands posts small fiscal 4Q loss' http://stks.co/3s9V
about 13 days ago by TradeBot
about 13 days ago by TradeBot
Human Genome Sciences (HGSI) Unanimously Rejects GlaxoSmithKline (GSK) Offer
May 17, 7:06AM Street Insider
May 17, 7:06AM Street Insider
$GSK Trametinib also in the spotlight at ASCO '12 with six presentations over 4 days. http://stks.co/3roL
about 13 days ago by abubnic
about 13 days ago by abubnic
$GSK Dabrafenib getting its share of attention at ASCO '12 with 50 presentations over 4 days. http://stks.co/3roI
about 13 days ago by abubnic
about 13 days ago by abubnic
$PFE $LLY $GSK So this is the condition some drug commercials warned us about! And we thought they were kidding. http://stks.co/3q2n
about 14 days ago by laughing_stock
about 14 days ago by laughing_stock
Don't see $XNPT popping 100% like $ARNA did, not as glamorous and still has to settle with $GSK. They would get 10 million if still partnrd
about 14 days ago by Glopolon
about 14 days ago by Glopolon
Barclays Maintains an 'Equalweight' on Human Genome Sciences (HGSI); Looking At $15/Share For GSK To Seal The Deal
May 14, 3:58PM Street Insider
May 14, 3:58PM Street Insider
$XNPT, No Debt, Drug has already been approved for RLS, so safety issues known. Court case with $GSK still out there, want settlement.
about 18 days ago by Glopolon
about 18 days ago by Glopolon
RT @JasonMilano8 $AMRN Here is a news about current CEO of Amarin selling his former company Reliant to ($GSK) in 2007: http://stks.co/3k0G
about 21 days ago by JasonMilano8
about 21 days ago by JasonMilano8
Breakfast Links | via @PointsnFigures http://stks.co/3jto $AMZN $GSK $HGSI $ZNGA
about 21 days ago by STNet
about 21 days ago by STNet
That's a surprise. $GSK goes hostile with $HGSI offer at 13. Did not expect that and am curious whether HGSI has something up its sleeve.
about 21 days ago by OysterX
about 21 days ago by OysterX
$AMRN Here is a news about current CEO of Amarin selling his former company Reliant to GlaxoSmithKline ($GSK) in 2007: http://stks.co/3jYt
about 21 days ago by JasonMilano8
about 21 days ago by JasonMilano8
$XNPT, Only non-dopaminergic option for RLS, is the advantage over generics. If $XNPT can work things out with $GSK, this should be $5+
about 21 days ago by Glopolon
about 21 days ago by Glopolon
Huf Post: Two Drugs Harness Immune System To Fight Cancer. http://stks.co/3iDa $DNDN $BMY $AZN $ONTY $GSK
about 22 days ago by abubnic
about 22 days ago by abubnic
$XNPT Sounds like Astellas is going to be better partner than $GSK, Hope they can work things out with $GSK re: Horizant.
about 23 days ago by Glopolon
about 23 days ago by Glopolon
$XNPT $GSK, FDA PDUFA date June 9th for Horizant treating postherpetic neuralgia. Horizant already approved in Japan for restless leg synd.
about 26 days ago by Glopolon
about 26 days ago by Glopolon
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GSK | 44.38 | +0.10 | +0.23% | 111.75B |
| GSIT | 4.18 | -0.02 | -0.48% | 120.25M |
| GSIG | 11.98 | +0.13 | +1.10% | 397.09M |
| GSI | 0.9874 | +0.12 | +13.48% | |
| GSH | 16.41 | +0.11 | +0.67% | 2.314B |
| GSB | 2.06 | -0.09 | -4.19% | 39.15M |
| GSAT | 0.391 | -0.01 | -3.43% | 120.61M |
| GS | 97.82 | +1.12 | +1.16% | 47.86B |
| GRZ | 3.40 | +0.11 | +3.34% | 195.89M |
| GRX | 8.14 | +0.04 | +0.49% |